MedPath
FDA Approval

Lithium

FDA-approved pharmaceutical product with comprehensive regulatory information, manufacturing details, and complete labeling documentation.

FDA Approval Summary

Company
Advagen Pharma Ltd
DUNS: 051627256
Effective Date
August 25, 2023
Labeling Type
HUMAN PRESCRIPTION DRUG LABEL
Lithium citrate(8 meq in 5 mL)

Manufacturing Establishments1

FDA-registered manufacturing facilities and establishments involved in the production, packaging, or distribution of this drug product.

Rubicon Research Private Limited

Advagen Pharma Ltd

737796233

Products1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Lithium

Product Details

NDC Product Code
72888-172
Application Number
ANDA218036
Marketing Category
ANDA (C73584)
Route of Administration
ORAL
Effective Date
August 25, 2023
WATERInactive
Code: 059QF0KO0RClass: IACT
SODIUM BENZOATEInactive
Code: OJ245FE5EUClass: IACT
ALCOHOLInactive
Code: 3K9958V90MClass: IACT
CITRIC ACID MONOHYDRATEInactive
Code: 2968PHW8QPClass: IACT
SORBITOLInactive
Code: 506T60A25RClass: IACT
SODIUM HYDROXIDEInactive
Code: 55X04QC32IClass: IACT
Code: 5Z6E9K79YVClass: ACTIMQuantity: 8 meq in 5 mL
© Copyright 2025. All Rights Reserved by MedPath